Is Anheuser-Busch InBev Stock a Buy? fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Even with the additional layer of evaluation, Salesforce still expects to close its deal for Slack in the quarter that ends on July 31, according to a regulatory filing.
The review, known as a second request, is not unprecedented: GE s 2017 Baker Hughes acquisition, Charles Schwab s 2020 TD Ameritrade deal and Anheuser-Busch s 2020 transaction with Craft Brew Alliance, which involved the sale of Kona Brewing s Hawaii operations to another company, all faced similar requests.
There are signs the U.S. might take a stronger approach to antitrust enforcement than it did under Barack Obama, CNBC reported in January. In Congress, Amy Klobuchar, a Democrat from Minnesota who became chair of the Senate s Judiciary subcommittee on antitrust this month, has proposed a sweeping reform of antitrust enforcement.
Hold up, just a few more questions.
Lindsay Clark Wed 17 Feb 2021 // 13:33 UTC Share
Copy
The US Department of Justice has written to Salesforce and Slack to ask a few questions about December s $28bn merger announcement.
Although complying with the request could potentially delay the deal, Salesforce said it anticipated completing the transaction during its fiscal quarter ending 31 July 2021.
The legal to-and-fro relates to the antitrust division of the DoJ sending a so-called second request to the companies asking for additional information and documentary material. Technically, the request extends the waiting period (under the Hart-Scott-Rodino Antitrust Improvements Act of 1976) until 30 days after Salesforce and Slack have complied with the request.
Between Dandelions, Inc. Announces Merger with Optimus Healthcare Services, Inc.
NEW YORK, NY / ACCESSWIRE / December 29, 2020 / Between Dandelions Inc (OTC PINK:HOPS) announced today the closing of a merger with Optimus Healthcare Services, Inc. ( Optimus or Company ).
Optimus, a company formed in 2020, controlled by KORR Acquisitions Group, Inc. ( KORR ), recently acquired control of Clinical Research Alliance, Inc. ( CRA ). Optimus was a portfolio company of KORR and as of the closing, KORR is now the controlling shareholder of Between Dandelions Inc. Between Dandelions Inc. will change its name to Optimus Healthcare Services Inc.
Optimus will focus on healthcare-related services.
The Company has appointed a new CEO, Marc Wiener. Prior to joining Optimus, Mr. Wiener was the founder of Orphan Pharmacy Services, which was sold in 2020, the co-founder of Linden Care Services, which sold to Belhealth Investment Partners in 2013, and Vitality Pharmaceutical Services, which sold t